BIO 2020 Notebook: FDA's Hahn On COVID-19 Lessons To Be Learned; NIH's Fauci On Health Care Disparities; Pfizer's Young On Forgoing Gov't Vaccine Funds
News and views from day three of BIO Digital. US FDA Commissioner Hahn asks industry to help identify best regulatory lessons from the pandemic; Pfizer’s chief business officer explains how need to move quickly in vaccine partnership with BioNTech led to decision to forgo US funding.
You may also be interested in...
More patient-centric trial designs also may be coming due to pandemic-related advances, Marks says.
Stephen Hahn also said the expedited approval process could be even more efficient.
US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.